Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 114.1% as of Mar 24th.</li>
<li>The average A-H premium changed by 0.6ppt week on week, led by information technology, industrials, utilities and offset by communication services, consumer discretionary, energy.</li>
<li>We highlight weekly changes in A-H premium for Dongfang Electric, CEEC, Great Wall Motor.</li>
</ul>


We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 114.1% as of Mar 24th.
The average A-H premium changed by 0.6ppt week on week, led by information technology, industrials, utilities and offset by communication services, consumer discretionary, energy.
We highlight weekly changes in A-H premium for Dongfang Electric, CEEC, Great Wall Motor.


A-H Premium Weekly (Mar 24th): Dongfang Electric, CEEC, Great Wall Motor

<ul>
<li>We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 111.9% as of Mar 3rd.</li>
<li>The average A-H premium changed by 0.3ppt week on week, led by communication services, consumer discretionary, financials and offset by real estate, information technology, industrials.</li>
<li>We highlight weekly changes in A-H premium for Xinjiang Goldwind, ZTE, China Southern, CRRC, GWM, China Telecom, CCCC, China Oilfield.</li>
</ul>


We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 111.9% as of Mar 3rd.
The average A-H premium changed by 0.3ppt week on week, led by communication services, consumer discretionary, financials and offset by real estate, information technology, industrials.
We highlight weekly changes in A-H premium for Xinjiang Goldwind, ZTE, China Southern, CRRC, GWM, China Telecom, CCCC, China Oilfield.


A-H Premium Weekly (Mar 3rd): Xinjiang Goldwind, ZTE, China Southern, CRRC, GWM, China Telecom

<ul>
<li>We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 111.6% as of Feb 24th.</li>
<li>The average A-H premium changed by 2.0ppt week on week, led by utilities, health care, financials and offset by information technology, industrials.</li>
<li>We highlight weekly changes in A-H premium for Xinjiang Gold Wind, China Shenhua, CICC, GWM, Shanghai Fudan.</li>
</ul>


We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 111.6% as of Feb 24th.
The average A-H premium changed by 2.0ppt week on week, led by utilities, health care, financials and offset by information technology, industrials.
We highlight weekly changes in A-H premium for Xinjiang Gold Wind, China Shenhua, CICC, GWM, Shanghai Fudan.


A-H Premium Weekly (Feb 24th): Xinjiang Gold Wind, China Shenhua, CICC, GWM, Shanghai Fudan

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>Pharmaron’s disappointing 2022 performance is just a start.Its business layout has always been "one step behind". CGT cannot become the main cornerstone business supporting valuation growth for the next stage.</li>
<li>The overall environment of CXO is different from that of the past. Even if Pharmaron finally achieves end-to-end integration,whether the prosperity of CXO industry still exists is a question mark.</li>
<li>Pharmaron may have entered a vicious circle, so that it is very challenging to generate the expected results no matter which direction the Company tries to break through.  </li>
</ul>


Pharmaron’s disappointing 2022 performance is just a start.Its business layout has always been "one step behind". CGT cannot become the main cornerstone business supporting valuation growth for the next stage.
The overall environment of CXO is different from that of the past. Even if Pharmaron finally achieves end-to-end integration,whether the prosperity of CXO industry still exists is a question mark.
Pharmaron may have entered a vicious circle, so that it is very challenging to generate the expected results no matter which direction the Company tries to break through.  


Pharmaron Beijing Co Ltd (3759.HK/300759.CH) - Start to Enter a Vicious Circle

<ul>
<li>We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 106.3% as of Jan 20th.</li>
<li>The average A-H premium changed by -2.6ppt week on week, led by financials, consumer staples, energy and offset by health care.</li>
<li>We highlight weekly changes in A-H premium for Haier Smart Home, Weichai Power, Fuyao Glass, China Shenhua, CSSC Offshore, Huaxin Cement, China Oilfield, CICC, China Life.</li>
</ul>


We analyse the changes of A-H premium on 143 stocks over the last week. The average A-H premium was 106.3% as of Jan 20th.
The average A-H premium changed by -2.6ppt week on week, led by financials, consumer staples, energy and offset by health care.
We highlight weekly changes in A-H premium for Haier Smart Home, Weichai Power, Fuyao Glass, China Shenhua, CSSC Offshore, Huaxin Cement, China Oilfield, CICC, China Life.


A-H Premium Weekly (Jan 20th): Haier Smart Home, Weichai Power, Fuyao Glass, China Shenhua

China

Maccura Biotechnology Co., Ltd. specializes in the research, development, manufacturing, sales, and service of in-vitro diagnostic products. The Company provides biochemistry, immunity, rapid detection, blood, molecular diagnosis, pathology, raw materials, and more. Maccura Biotechnology conducts business in China.

Guangzhou Boji Medical & Biotechnological Co., Ltd. is an outsourcing drug research and development company. The Company provides pharmaceutical companies the ability to conduct its researches and developments at lower cost levels and offers support to bring drugs and devices to the Chinese market quicker.

Guangzhou Improve Medical Instruments Co., Ltd. researches, develops, and manufactures medical instruments. The Company's products include evacuated blood collection system, microbe specimen collection and transport, clinical testing reagent, equipment for clinical specimen testing & processing, etc.

Viva Biotech Holdings operates as a drug discovery platform. The Company provides target protein expression, structure researching, hit screening, drug candidate determination, and other services. Viva Biotech Holdings serves customers worldwide.

Austar Lifesciences Limited provides integrated engineering solutions with services and products for pharmaceutical manufacturers and research institutes in China and other emerging countries. The Company also manufactures, sells and distributes pharmaceutical equipment and life science consumables.

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

Consun Pharmaceutical Group Limited is a pharmaceutical company engaged in the research, manufacturing and sale of modern Chinese medicines and medical contrast medium in the People's Republic of China.

Hunan Er-kang Pharmaceutical Company Limited develops, produces and sells pharmaceutical products. The Company's main product include pharmaceutical excipients and antibiotic products.

Guizhou Bailing Group Pharmaceutical Co, Ltd. is a pharmaceutical company.  The Company's products include tablets, capsules, syrup, soft capsules, granules, pills, and powder.

Gz Bailing Group Pharm Co., Ltd. (002424 CH)

Zhejiang International Group Co., Ltd. mainly manufactures pharmaceutical products, including medicines, healthcare products, medical instruments, and pharmaceutical raw materials.  The Company also manufactures textile products, develops real estate, and provides technical services.

Standard BioTools Inc. offers technologies that help biomedical researchers develop medicines. The Company offers reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes.

PureTech Health plc operates as a healthcare company. The Company researches and licenses technology and videogames which are used as a treatment for neurological problems.

Ergomed plc provides clinical research, and drug development and safety services in the United Kingdom and rest of Europe, the Middle East, Africa, North America, Asia, and Australia. The company offers clinical development, trial management services, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, neurology, and immunology, as well as the development of orphan drugs. The company?s clinical development services include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It also provides late phase services, such as strategy and study design, medical training, regulatory consultancy, management of ISTs, full study management, publication management, site management, pharmacovigilance, tailored data capture solutions, REMS and RMPs, and medical information services; and co-development services for pharma and biotech companies. In addition, the company is involved in the studies of ultra-rare diseases, including infantile hypophsophatemia, paroxyzmal nocturnal haemoglobinuria, and primary hyperoxaluria; and the provision of the specialized site management model that allows smooth interaction of the sites and patient organizations, and advocacy groups. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed Plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Quanterix Corporation develops ultra-sensitive detection systems for use in research and in-vitro diagnostics. The Company offers automated immunoassay technology for detection and quantification of biomarkers in in-vitro and companion diagnostics and blood screening. Quanterix provides its products in life science, oncology, and neurology research in the United States.

Pacific Biosciences of California Inc. has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein.  The Company's system enables real-time analysis of biomolecules with single molecule resolution.

Pacific Biosciences Of California (PACB US)

Shin Nippon Biomedical Laboratories Ltd is a contract research organization. The Company provides pre-clinical testing services in the pharmaceutical industry.

CMIC Holdings Co., Ltd. is a Contract Research Organization (CRO) who provides medical research related services mainly to pharmaceuticals and medical organizations. Its service ranges from strategy and regulatory consulting, clinical monitoring,and data management.

Selvita Spolka Akcyjna operates as a pharmaceutical company. The Company discovers drugs, as well as provides research and development services. Selvita serves customers worldwide.

Genfit is a biopharmaceutical company.  The Company researches treatments for cardiovascular, metabolic and inflammatory diseases, and age-linked neurodegenerative disorders.

Personalis, Inc. provides genomic sequencing and analytics solutions. The Company supports the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Personalis serves customers worldwide.

Joinn Laboratories (China) Co., Ltd. operates as a medicines development company. The Company offers drug development, pharmaceutical analysis, pharmacologic testing, and other related services. Joinn Laboratories (China) also provides pesticide and medical device safety evaluation services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Joinn Laboratories China Lt (6127 HK)

A-H Premium Weekly (Mar 24th): Dongfang Electric, CEEC, Great Wall Motor

We analyzed WoW changes in A-H premium and highlight changes in A-H premium for Dongfang Electric, CEEC, Great Wall Motor.

Ke Yan, CFA, FRM

A-H Premium Weekly (Mar 3rd): Xinjiang Goldwind, ZTE, China Southern, CRRC, GWM, China Telecom

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Xinjiang Goldwind, ZTE, China Southern, CRRC, GWM, China...

Ke Yan, CFA, FRM

A-H Premium Weekly (Feb 24th): Xinjiang Gold Wind, China Shenhua, CICC, GWM, Shanghai Fudan

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Xinjiang Gold Wind, China Shenhua, CICC, GWM, Shanghai Fudan.

Ke Yan, CFA, FRM

Pharmaron Beijing Co Ltd (3759.HK/300759.CH) - Start to Enter a Vicious Circle

Due to slow layout in end-to-end integration/high uncertainty in CGT, Pharmaron has entered a vicious circle as CXO's fast-growing dividend period...

Xinyao (Criss) Wang

A-H Premium Weekly (Jan 20th): Haier Smart Home, Weichai Power, Fuyao Glass, China Shenhua

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Haier Smart Home, Weichai Power, Fuyao Glass, China Shenhua.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)